Picó-Guzmán Francisco Javier, Martínez-Montañez Olga Georgina, Ruelas-Barajas Enrique, Hernández-Ávila Mauricio
LifeSciences Consultants, Consultoría Estratégica. Ciudad de México, México.
Instituto Mexicano del Seguro Social, Dirección de Prestaciones Económicas y Sociales, Coordinación Normativa. Ciudad de México, México.
Rev Med Inst Mex Seguro Soc. 2022 Dec 19;60(Suppl 2):S86-S95.
In Mexico, diabetes mellitus (DM) and diseases cardiovascular, register an upward trend.
To estimate the number of complications due to cardiovascular events (CVD) and complications derived from DM (CDM) accumulated in beneficiaries of the Mexican Institute of Social Security (IMSS) from 2019 to 2028, as well as the expense for medical and economic benefits in a scenario baseline and one of change in metabolic profile due to lack of medical follow-up during the COVID-19 pandemic.
The number of CVD and CDM was estimated from 2019, with a 10-year risk projection using the ESC CVD Risk Calculator and United Kingdom Prospective Diabetes Study, considering risk factors registered in the institutional databases.
From 2019 to 2028, cumulative CVD cases were estimated at 2 million and those of CDM in 960 thousand, with an impact on medical spending of 439,523 million pesos and on the economic benefits of 174,085 millions. When considering the COVID-19 pandemic, CVD events and CDM increased by 589 thousand, with an increase in spending of 93,787 million pesos for medical care and 41,159 million for economic benefits.
Without a comprehensive intervention in the management of CVD and CDM, the cost by both diseases will continue to increase, with financial pressures getting older.
在墨西哥,糖尿病(DM)和心血管疾病呈上升趋势。
估计2019年至2028年墨西哥社会保障局(IMSS)受益人中因心血管事件(CVD)累积的并发症数量以及糖尿病(CDM)引发的并发症数量,以及在基线情景和因新冠疫情期间缺乏医疗随访导致代谢状况改变的情景下的医疗费用和经济收益。
从2019年开始估计CVD和CDM的数量,使用欧洲心脏病学会CVD风险计算器和英国前瞻性糖尿病研究进行10年风险预测,考虑机构数据库中记录的风险因素。
2019年至2028年,估计累积CVD病例为200万例,CDM病例为96万例,对医疗支出的影响为4395.23亿比索,对经济收益的影响为1740.85亿比索。考虑到新冠疫情,CVD事件和CDM增加了58.9万例,医疗护理支出增加了937.87亿比索,经济收益增加了411.59亿比索。
如果不对CVD和CDM的管理进行全面干预,这两种疾病的成本将继续增加,财政压力也会越来越大。